These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

424 related articles for article (PubMed ID: 12975222)

  • 1. Efficacy and safety of cholinesterase inhibitors in Alzheimer's disease: a meta-analysis.
    Lanctôt KL; Herrmann N; Yau KK; Khan LR; Liu BA; LouLou MM; Einarson TR
    CMAJ; 2003 Sep; 169(6):557-64. PubMed ID: 12975222
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Galantamine for Alzheimer's disease.
    Olin J; Schneider L
    Cochrane Database Syst Rev; 2001; (4):CD001747. PubMed ID: 11687119
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ginkgo biloba Extract (EGb761), Cholinesterase Inhibitors, and Memantine for the Treatment of Mild-to-Moderate Alzheimer's Disease: A Network Meta-Analysis.
    Thancharoen O; Limwattananon C; Waleekhachonloet O; Rattanachotphanit T; Limwattananon P; Limpawattana P
    Drugs Aging; 2019 May; 36(5):435-452. PubMed ID: 30937879
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Galantamine for Alzheimer's disease.
    Olin J; Schneider L
    Cochrane Database Syst Rev; 2002; (3):CD001747. PubMed ID: 12137632
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Donepezil for dementia due to Alzheimer's disease.
    Birks JS; Harvey RJ
    Cochrane Database Syst Rev; 2018 Jun; 6(6):CD001190. PubMed ID: 29923184
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rivastigmine for Alzheimer's disease.
    Birks JS; Grimley Evans J
    Cochrane Database Syst Rev; 2015 Apr; (4):CD001191. PubMed ID: 25858345
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of cholinesterase inhibitor utilization patterns and associated health care costs in Alzheimer's disease.
    Mucha L; Shaohung S; Cuffel B; McRae T; Mark TL; Del Valle M
    J Manag Care Pharm; 2008 Jun; 14(5):451-61. PubMed ID: 18597574
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Galantamine for Alzheimer's disease.
    Olin J; Schneider L
    Cochrane Database Syst Rev; 2001; (1):CD001747. PubMed ID: 11279727
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Withdrawal or continuation of cholinesterase inhibitors or memantine or both, in people with dementia.
    Parsons C; Lim WY; Loy C; McGuinness B; Passmore P; Ward SA; Hughes C
    Cochrane Database Syst Rev; 2021 Feb; 2(2):CD009081. PubMed ID: 35608903
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rivastigmine for Alzheimer's disease.
    Birks J; Grimley Evans J; Iakovidou V; Tsolaki M; Holt FE
    Cochrane Database Syst Rev; 2009 Apr; (2):CD001191. PubMed ID: 19370562
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials.
    Kavirajan H; Schneider LS
    Lancet Neurol; 2007 Sep; 6(9):782-92. PubMed ID: 17689146
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rivastigmine for Alzheimer's disease.
    Birks J; Grimley Evans J ; Iakovidou V; Tsolaki M
    Cochrane Database Syst Rev; 2000; (4):CD001191. PubMed ID: 11034705
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discontinuation of cholinesterase inhibitor treatment and determinants thereof in the Netherlands: A retrospective cohort study.
    Kröger E; van Marum R; Souverein P; Egberts T
    Drugs Aging; 2010 Aug; 27(8):663-75. PubMed ID: 20658794
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The comparative efficacy and safety of cholinesterase inhibitors in patients with mild-to-moderate Alzheimer's disease: a Bayesian network meta-analysis.
    Kobayashi H; Ohnishi T; Nakagawa R; Yoshizawa K
    Int J Geriatr Psychiatry; 2016 Aug; 31(8):892-904. PubMed ID: 26680338
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The benefits and risks associated with cholinesterase inhibitor therapy in Alzheimer's disease.
    Thompson S; Lanctôt KL; Herrmann N
    Expert Opin Drug Saf; 2004 Sep; 3(5):425-40. PubMed ID: 15335298
    [TBL] [Abstract][Full Text] [Related]  

  • 16. WITHDRAWN: Tacrine for Alzheimer's disease.
    Qizilbash N; Birks J; Lopez Arrieta J; Lewington S; Szeto S
    Cochrane Database Syst Rev; 2007 Jul; (3):CD000202. PubMed ID: 17636619
    [TBL] [Abstract][Full Text] [Related]  

  • 17. To treat or not to treat? A meta-analysis of the use of cholinesterase inhibitors in mild cognitive impairment for delaying progression to Alzheimer's disease.
    Diniz BS; Pinto JA; Gonzaga ML; Guimarães FM; Gattaz WF; Forlenza OV
    Eur Arch Psychiatry Clin Neurosci; 2009 Jun; 259(4):248-56. PubMed ID: 19224111
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Galantamine for Alzheimer's disease and mild cognitive impairment.
    Loy C; Schneider L
    Cochrane Database Syst Rev; 2006 Jan; 2006(1):CD001747. PubMed ID: 16437436
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Memantine for dementia.
    McShane R; Westby MJ; Roberts E; Minakaran N; Schneider L; Farrimond LE; Maayan N; Ware J; Debarros J
    Cochrane Database Syst Rev; 2019 Mar; 3(3):CD003154. PubMed ID: 30891742
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's disease.
    Rolinski M; Fox C; Maidment I; McShane R
    Cochrane Database Syst Rev; 2012 Mar; 2012(3):CD006504. PubMed ID: 22419314
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.